Jun 17, 2020
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
Jun 04, 2020
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
May 28, 2020
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
May 12, 2020
Protagonist Therapeutics, Inc. Announces Upsizing and Pricing of Underwritten Public Offering of 7,000,000 Shares of Common Stock
May 11, 2020
Protagonist Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Common Stock
May 07, 2020
Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
May 07, 2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
May 04, 2020
Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update
Mar 10, 2020
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Mar 02, 2020
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results
Mar 02, 2020
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results
Mar 02, 2020
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results
Mar 02, 2020
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results
Feb 19, 2020
Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York
Feb 07, 2020
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)
Jan 07, 2020
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
Jan 06, 2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
Dec 03, 2019
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
Nov 13, 2019
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
Nov 06, 2019
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease